Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma

ABSTRACT: BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma

PROVIDER: PRJNA785569 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17096538_1.fastq.gz	Fastqsanger.gz
	SRR17096538_2.fastq.gz	Fastqsanger.gz
	SRR17096539_1.fastq.gz	Fastqsanger.gz
	SRR17096539_2.fastq.gz	Fastqsanger.gz
	SRR17096540_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma

Project description:Neuroblastoma (NB) is the most common extracranial solid tumor of childhood, which is derived from primordial neural crest cells. GNE987 is a newly developed von Hippel-Lindau tumor suppressor (VHL)-based pan-BET-targeting PROTAC, which can bind to the target proteins (BET proteins, including BRD2, BRD3, and BRD4) and recruit them to the ubiquitin/ proteasome system for selective degradation. However, the function of GNE987 has not been assessed in NB models so far. In the present study, RNA-seq analysis was performed to explore the effect of GNE987 on NB cells.

2022-03-23 | GSE190002 | GEO

BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma (ChIP-Seq)

Project description:BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma (ChIP-Seq)

| PRJNA800647 | ENA

BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma (ChIP-Seq)

Project description:Neuroblastoma (NB) is the most common extracranial solid tumor of childhood, which is derived from primordial neural crest cells. GNE987 is a newly developed von Hippel-Lindau tumor suppressor (VHL)-based pan-BET-targeting PROTAC, which can bind to the target proteins (BET proteins, including BRD2, BRD3, and BRD4) and recruit them to the ubiquitin/ proteasome system for selective degradation. However, the function of GNE987 has not been assessed in NB models so far. In the present study, ChIP-Seq analysis was performed to explore the effect of GNE987 on NB cells.

2022-03-23 | GSE194430 | GEO

BRD4 inhibitor GNE987 exerts anti-cancer effects in Osteosarcoma

Project description:BRD4 inhibitor GNE987 exerts anti-cancer effects in Osteosarcoma

| PRJNA1019364 | ENA

BRD4 inhibitor GNE987 exerts anti-cancer effects in Osteosarcoma

Project description:GNE987 is a newly developed von Hippel-Lindau tumor suppressor (VHL)-based pan-BET-targeting PROTAC, which can bind to the target proteins (BET proteins, including BRD2, BRD3, and BRD4) and recruit them to the ubiquitin/proteasome system for selective degradation. In the our study, ChIP-Seq analysis was performed to explore the effect of GNE987 on osteosarcoma cells.

2024-08-08 | GSE243673 | GEO

BRD4 inhibitor MZ1 exerts anti-cancer effects in Neuroblastoma

Project description:BRD4 inhibitor MZ1 exerts anti-cancer effects in Neuroblastoma

| PRJNA797669 | ENA

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting C-Myc and S100A16 in Glioblastoma [ChIP-seq]

Project description:Glioblastoma (GBM) in children is a relatively more common primary central nervous system tumor with a high degree of malignancy, high mortality, and complex surgical complete resection.. GNE987 is a newly developed von Hippel-Lindau tumor suppressor (VHL)-based pan-BET-targeting PROTAC, which can bind to the target proteins (BET proteins, including BRD2, BRD3, and BRD4) and recruit them to the ubiquitin/ proteasome system for degradation. However, the function of GNE987 has not been assessed in GBM cells so far. In the present study, ChIP-Seq analysis was performed to explore the effect of GNE987 on GBM cells.

2022-11-09 | GSE202484 | GEO

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting C-Myc and S100A16 in Glioblastoma

Project description:BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting C-Myc and S100A16 in Glioblastoma

| PRJNA835712 | ENA

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting C-Myc and S100A16 in Glioblastoma

Project description:To investigate the function of GNE987 in the regulation of gene expression, we treated U87 cells with control (DMSO) or GNE987, respectively. We then performed gene expression profiling analysis using data obtained from RNA-seq of control and GNE987 treatment.

2022-11-09 | GSE202362 | GEO

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting C-Myc and S100A16 in Glioblastoma [ChIP-seq]

Project description:BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting C-Myc and S100A16 in Glioblastoma [ChIP-seq]

| PRJNA836277 | ENA